SEC Filing · 6-K
Immatics N.V.
IMTXNASDAQEQUITYCurrent
SEC Filing
Company context
Immatics is committed to making a meaningful impact on the lives of patients with cancer. We are the global leader in precision targeting of PRAME, a target expressed in more than 50 cancers. Our cutting-edge science and robust clinical pipeline form the broadest PRAME franchise with the most PRAME indications and modalities, spanning TCR T-cell therapies and TCR bispecifics. Immatics intends to use its website www.immatics.com as a means of disclosing material non-public information. For regular updates, you can also follow us on LinkedIn and Instagram.
Current securities
Historical securities (1)
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗